PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsBreast cancer drug reduces the risk of recurrence by 42 percent

BioNews

Breast cancer drug reduces the risk of recurrence by 42 percent

Published 4 June 2021 posted in News and appears in BioNews 1098

Author

Dr Charlott Repschläger

PET BioNews

A targeted breast cancer treatment reduces the risk of BRCA-related cancer returning or spreading after chemotherapy...

A targeted breast cancer treatment reduces the risk of BRCA-related cancer returning or spreading after chemotherapy.

The PARP-inhibitor olaparib (Lynparza) inhibits a cancer cell's ability to repair damage to their DNA by trapping the PARP protein, causing further DNA damage and cell death. The drug is the first in its class and has already been approved for a range of advanced PARP-dependent cancers, including certain types of ovarian, breast, pancreatic and prostate cancer.

Dr Sue Friedman, executive director of Facing Our Risk of Cancer Empowered (FORCE) and member of the OlympiA trial steering committee, said: 'While there have been great strides in the early treatment of breast cancer, the fear of cancer returning is still at the forefront of patients' minds. New targeted treatment approaches are needed in the adjuvant setting that can help keep cancer and that fear at bay.'

The OlympiA stage III multicentre clinical trial in patients with BRCA-mutated high-risk early-stage breast cancer was coordinated by several funders, including the US National Cancer Institute and the Institute of Cancer Research, London. Results were published in the New England Journal of Medicine.

Over 1800 patients with germline BRCA-mutated high-risk, HER2-negative early breast cancer completed local treatment and standard chemotherapy before being given either olaparib or a placebo tablet.

After three years 85.9 percent of patients who received olaparib showed no signs of the cancer returning, compared to 77.1 percent of patients in the placebo group. The trial also showed that 87.5 percent of patients receiving olaparib remained free of metastasis, compared to 80.4 percent in the placebo group.

BRCA1 and BRCA2 mutations are found in about 5 percent of breast cancer patients and can lead to problems in the cell's DNA repair mechanisms. This makes the cell's DNA more unstable and likely to accumulate more mutations that can lead to cancer, but also renders the cells more susceptible to drugs like olaparib.

'We are thrilled that our global academic and industry partnership in OlympiA has been able to help identify a possible new treatment option for patients with early-stage breast cancer and who have inherited mutations in their BRCA1 or BRCA2 genes. Patients with early-stage breast cancer who have inherited BRCA mutations are typically diagnosed at a younger age compared to those without such a mutation' said Professor Andrew Tutt, chair of the OlympiA trial steering committee and professor of oncology at the Institute of Cancer Research, London and King's College London.

He added: 'Olaparib has the potential to be used as a follow-on to all the standard initial breast cancer treatments to reduce the rate of life-threatening recurrence and cancer spread for many patients identified through genetic testing to have mutations in these genes.'

Sources and References

  • 03/06/2021
    AstraZeneca
    Lynparza reduced the risk of cancer recurrence by 42 percent in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial
  • 03/06/2021
    The New England Journal of Medicine
    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
  • 04/06/2021
    The Times
    Breast cancer drug could beat the 'Jolie gene'
  • 03/06/2021
    Evening Standard
    Scientists hail breakthrough in breast cancer treatment
  • 04/06/2021
    ITV
    'Major breakthrough' in breast cancer treatment, scientists say
  • 03/06/2021
    Daily Mail
    'Jolie gene' drug can slash breast cancer danger: Daily pill cuts risk of a relapse in women with the faulty BRCA gene by 42 percent, study shows

Related Articles

PET BioNews
News
18 June 2021 • 2 minutes read

Potential new approach identified for treating BRCA-related cancers

by Christina Burke

A new class of drug could effectively treat types of breast, ovarian and prostate cancer...

PET BioNews
News
23 April 2021 • 2 minutes read

Olaparib extends life of ovarian cancer patients with BRCA1/2

by Hannah Flynn

Cancer treatment olaparib has been shown to extend the life of relapsed ovarian cancer patients with mutations in BRCA1 and BRCA2, by nearly 13 months, when used as a maintenance therapy...

PET BioNews
News
20 March 2017 • 2 minutes read

Existing drugs could benefit one in five breast cancer patients

by Dr Molly Godfrey

A genetic study of breast cancer patients suggests that existing drugs for treating rare breast and ovarian cancers may help more patients than previously thought...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 January 2017 • 2 minutes read

More women get tested for breast cancer genes thanks to 'Angelina Jolie effect'

by Anastassia Bolotkova

Angelina Jolie's 2013 public announcement that she has the BRCA1 breast cancer gene led to a 64 percent increase in women seeking genetic testing for breast cancer...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
27 March 2015 • 3 minutes read

Angelina Jolie has ovaries and fallopian tubes removed to reduce BRCA risk

by Sophie McLachlan

In an article in the New York Times, Angelina Jolie has revealed her decision to have her ovaries and fallopian tubes removed, in her on-going battle to reduce her risk of cancer...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Cambridgeshire CCG to review IVF policy

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Common virus may be cause of recent hepatitis cases in children

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

1 August 2022 • 2 minutes read

CRISPR genome editing treatments may raise cancer risk

1 August 2022 • 2 minutes read

Differences in IVF-conceived children's size disappear by adolescence

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856